Evidence map›Paper›PMID 33924869›Full record

ArticleNanomaterials (Basel, Switzerland)2021

Biodistribution of Poly(alkyl cyanoacrylate) Nanoparticles in Mice and Effect on Tumor Infiltration of Macrophages into a Patient-Derived Breast Cancer Xenograft.

Abhilash D Pandya, Tore-Geir Iversen, Siver Moestue, Maria T Grinde, Ýrr Mørch, Sofie Snipstad, Andreas K O Åslund, Geir F Øy, Wanja Kildal, Olav Engebråten and 3 more

Open access · goldAbstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Abhilash D PandyaDepartment of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, 0379 Oslo, Norway.ORCID 0000-0002-7713-3050
Tore-Geir IversenDepartment of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, 0379 Oslo, Norway.ORCID 0000-0003-1148-6117
Siver MoestueDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491 Trondheim, Norway.ORCID 0000-0002-1940-5695
Maria T GrindeDepartment of Circulation and Medical Imaging, Norwegian University of Science and Technology, 7491 Trondheim, Norway.
Ýrr MørchSINTEF AS, Department of Biotechnology and Nanomedicine, 7034 Trondheim, Norway.ORCID 0000-0001-5182-7276
Sofie SnipstadSINTEF AS, Department of Biotechnology and Nanomedicine, 7034 Trondheim, Norway.ORCID 0000-0003-1732-7168
Andreas K O ÅslundSINTEF AS, Department of Biotechnology and Nanomedicine, 7034 Trondheim, Norway.ORCID 0000-0001-5222-9307
Geir F ØyDepartment of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, 0379 Oslo, Norway.
Wanja KildalInstitute for Cancer Genetics and Informatics, Oslo University Hospital, The Norwegian Radium Hospital, 0379 Oslo, Norway.ORCID 0000-0002-9639-6868
Olav EngebråtenDepartment of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, 0379 Oslo, Norway.
Kirsten SandvigDepartment of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, 0379 Oslo, Norway.ORCID 0000-0002-4174-9072
Tore SkotlandDepartment of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, 0379 Oslo, Norway.ORCID 0000-0002-6524-612X
Gunhild M MælandsmoDepartment of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, 0379 Oslo, Norway.ORCID 0000-0002-4797-1600
Oslo University Hospital · NOSINTEF · NONorwegian University of Science and Technology · NO

Funding

Norges Forskningsråd 228200/O70
6 · The paper itself

Abstract

We have investigated the biodistribution and tumor macrophage infiltration after intravenous injection of the poly(alkyl cyanoacrylate) nanoparticles (NPs): PEBCA (poly(2-ethyl-butyl cyanoacrylate), PBCA (poly(n-butyl cyanoacrylate), and POCA (poly(octyl cyanoacrylate), in mice. These NPs are structurally similar, have similar PEGylation, and have previously been shown to give large variations in cellular responses in vitro. The PEBCA NPs had the highest uptake both in the patient-derived breast cancer xenograft MAS98.12 and in lymph nodes, and therefore, they are the most promising of these NPs for delivery of cancer drugs. High-resolution magic angle spinning magnetic resonance (HR MAS MR) spectroscopy did not reveal any differences in the metabolic profiles of tumors following injection of the NPs, but the PEBCA NPs resulted in higher tumor infiltration of the anti-tumorigenic M1 macrophages than obtained with the two other NPs. The PEBCA NPs also increased the ratio of M1/M2 (anti-tumorigenic/pro-tumorigenic) macrophages in the tumors, suggesting that these NPs might be used both as a vehicle for drug delivery and to modulate the immune response in favor of enhanced therapeutic effects.

Indexed as

biodistributionbreast cancermacrophage infiltrationmagnetic resonance spectroscopypoly(alkyl cyanoacrylate) nanoparticles

Identifiers

PMID33924869
PMCPMC8145722
OpenAlexW3158667997

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.